Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc., headquartered in the United States, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative medicines. Founded in 2018, the company has quickly established itself as a leader in providing unique formulations tailored for patients with specific needs, particularly in the paediatric and rare disease sectors. With a focus on high-quality, patient-centric products, Azurity's core offerings include specialised oral liquid medications that address significant gaps in treatment options. The company’s commitment to enhancing patient outcomes through customised solutions sets it apart in a competitive market. Notable achievements include rapid growth and recognition for its contributions to improving access to essential therapies, solidifying Azurity's position as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Azurity Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Azurity Pharmaceuticals, Inc.'s score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Azurity Pharmaceuticals, Inc.'s reported carbon emissions
Azurity Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented reduction targets or climate commitments available from the company. As of now, Azurity Pharmaceuticals has not established any significant climate initiatives or pledges, nor does it inherit emissions data from a parent company or corporate family. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting framework. In the context of the pharmaceutical industry, it is increasingly important for companies to set measurable climate targets and engage in sustainability practices to mitigate their environmental impact. Without specific data or commitments, Azurity Pharmaceuticals may face challenges in aligning with industry standards and expectations regarding carbon emissions and climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Azurity Pharmaceuticals, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
